GlassScriptPhysician profile
Alexander Robert Harris
NPI 1437562451
$9,268.22
in general payments reported to CMS, 2019-2025
36 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $353 · 2021: $810 · 2022: $750 · 2023: $2,860 · 2024: $1,995 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,351 · Honoraria: $1,515 · Long Term Medical Supply Or Device Loan: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,350.64 |
| Honoraria | $1,515.28 |
| Long Term Medical Supply Or Device Loan | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,197.48 | 2020-2023 | Tepezza |
| Alcon Vision LLC | $1,391.75 | 2020-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Abbvie INC. | $1,194.36 | 2022-2025 | |
| Sight Sciences, INC. | $975.88 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $723.96 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $438.47 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $351.06 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Amgen INC. | $327.60 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $319.79 | 2019-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $146.15 | 2019-2024 | |
| Aerie Pharmaceuticals, INC. | $125.00 | 2019 | |
| Allergan, INC. | $104.50 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $99.53 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $96.56 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $84.08 | 2022-2024 | Acthar |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $65.19 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.78 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $54.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.77 | 2022 | |
| Omeros Corporation | $40.08 | 2019-2021 | |
| Merz North America, INC. | $37.76 | 2019-2020 | |
| Edwards Lifesciences Corporation | $35.79 | 2024 | |
| Eyepoint US, INC. | $35.51 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $33.47 | 2021 | |
| Lilly USA, LLC | $27.68 | 2022 | |
| Harrow Eye, LLC | $27.61 | 2024 | Vevye |
| Rayner Intraocular Lenses Limited | $27.20 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Biohaven Pharmaceutical Holding Company LTD. | $25.68 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.31 | 2023 | Dupixent |
| Boston Scientific Corporation | $23.46 | 2021 | |
| Dompe US, INC. | $22.48 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $22.29 | 2025 | Syfovre |
| Tearlab Corp | $21.31 | 2020 | |
| Glaukos Corporation | $20.56 | 2025 | Idosetr |
| Thea Pharma INC. | $17.60 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $15.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.